1 # Cardiovascular effects and molecular mechanisms of

2 # bisphenol A and its metabolite MBP in zebrafish

3 *A Ross Brown†, Jon M Green†, John Moreman†, Lina M Gunnarsson†, Sulayman Mourabit†,*

4 *Jonathan Ball†, Matthew J Winter†, Maciej Trznadel†, Ana Correia†, Christian Hacker†, Alexis*

5 *Perry†, Mark E Wood†, Malcolm J Hetheridge†, Richard A Currie‡, Charles R Tyler†**

6 †Biosciences, College of Life and Environmental Sciences, University of Exeter, Geoffrey Pope,

7 Stocker Road, Exeter, Devon, EX4 4QD, UK.

8 ‡Jealott's Hill International Research Centre, Syngenta, Bracknell, Berkshire, RG42 6EY, UK.

9 * Corresponding author - Email: c.r.tyler@exeter.ac.uk.

10 **KEYWORDS**

11 BPA, metabolite, MBP, endocrine, effects, estrogenic, heart valves, transgenic, zebrafish

12 **ABSTRACT**

13 The plastic monomer bisphenol A (BPA) is one of the highest production volume chemicals in the

14 world and is frequently detected in wildlife and humans, particularly children. BPA has been

15 associated with numerous adverse health outcomes relating to its estrogenic and other hormonal

16 properties, but direct causal links are unclear in humans and animal models. Here we simulated

17 measured (1×) and predicted worst-case (10×) maximum foetal exposures for BPA, or equivalent

1

18   concentrations of its metabolite MBP, using fluorescent reporter embryo-larval zebrafish, capable

19   of quantifying Estrogen Response Element (ERE) activation throughout the body. Heart valves

20   were primary sites for ERE activation by BPA and MBP, and transcriptomic analysis of micro-

21   dissected heart tissues showed that both chemicals targeted several molecular pathways

22   constituting biomarkers for calcific aortic valve disease (CAVD), including extra-cellular matrix

23   (ECM) alteration. ECM collagen deficiency and impact on heart valve structural integrity were

24   confirmed by histopathology for high-level MBP exposure, and structural defects (abnormal

25   curvature) of the atrio-ventricular valves corresponded with impaired cardiovascular function

26   (reduced ventricular beat rate and blood flow). Our results are the first to demonstrate plausible

27   mechanistic links between ERE activation in the heart valves by BPA's reactive metabolite MBP

28   and the development of valvular-cardiovascular disease states.

29   **INTRODUCTION**

30   Over 1400 chemicals have been identified as potential endocrine disrupting chemicals (EDCs) (1)

31   with potential to "alter function(s) of the endocrine system and consequently cause adverse health

32   effects in an intact organism, or its progeny, or (sub)populations" (2-5). Over 100 of these

33   chemicals are regarded internationally as priority EDCs and almost half (45%) are estrogenic i.e.

34   estrogen receptor (ER) and/or estrogen-related receptor (ERR) agonists (6-8). Estrogens play a

35   fundamental role in the formation and function of numerous organs and systems (9) and

36   imbalances are known to increase risks of cancers and disorders of reproductive, nervous,

37   metabolic, immune and cardiovascular systems in various animal models and humans (10-14).

38   However, linking cause and effect remains a major challenge in chemical risk/safety assessment.

39   Bisphenol A (BPA) is associated with the above disorders and is one of the world's highest

40 production volume chemicals (15), to which humans are continually exposed via plastic and other

41 products (16-23). Reported BPA-effect mechanisms include agonism of nuclear ERs (24), ERRs

42 (25,26), membrane ERs (27,28), epigenetic modulation of estrogen response elements (EREs)

43 (29,30) and weak agonism of androgen and thyroid (T3) receptors (31,32). Over 2700 peer-

44 reviewed papers have been published on the endocrine effects of BPA (Scopus search, September

45 2018) illustrating the level of scientific interest in BPA. Despite this high number of studies, 10%

46 of which are *in vivo* studies, regulatory authorities have concluded that there is insufficient

47 evidence to establish causal links between BPA and adverse effects on human health (21,33,34).

48 Nevertheless, public pressure has prompted the removal of BPA from baby products in Canada,

49 Europe and North America (35,36), due to higher exposures and lower competence for

50 metabolising BPA in infants (17,37). Some of the replacement products for BPA are also

51 estrogenic in mammals (38) and fish (39). Furthermore, the reactive BPA metabolite 4-methyl-

52 2,4-bis(p-hydroxyphenyl)pent-1-ene (MBP) has been shown to be far more potent than the parent

53 BPA in terms of: estrogen receptor binding and activation *in vitro* ($\times$10-1000) (40); stimulation of

54 uterine growth in rats ($\times$500) (41); elevated estrogen receptor (*esr1*) and vitellogenin (*vtg1, vtg2*)

55 gene and protein expression in medaka (*Oryzias latipes*) ($\times$250-400) (42,43); ERE activation in

56 zebrafish (*Danio rerio*) ($\times$1000) via *esr1* (44). These findings indicate an urgent need for more

57 integrative test systems capable of evaluating multiple effect levels, linking key molecular events

58 and adverse outcomes for chemicals like BPA and its analogues and metabolites.

59 Transgenic (TG) zebrafish models offer suitable integrative test systems, whereby key molecular

60 events (e.g. (ant)agonism of hormone receptors, or hormone metabolism) can be identified and

61 quantified by fluorescent protein reporters linked to specific enzymes, receptors or response

62 elements (45). Spatial and temporal resolution of key molecular events in TG zebrafish can

63 facilitate the detection of chemical effects throughout the body *in vivo*, in real time (45-49) and

64 can help establish causal links with subsequent adverse effects on biological development and/or

65 function (39,44). Here we exploit TG(ERE:GFP)Casper zebrafish to study the effects of BPA and

66 its highly estrogenic metabolite MBP on cardiovascular (CV) development and function, building

67 on previous work using this model, which highlighted the heart, and heart valves in particular, as

68 being key targets for these compounds (39,44,47,48).

69

70 **MATERIALS AND METHODS**

71 **Test substances**

72 Bisphenol A or BPA: 2,2-bis(4-hydroxyphenyl)propane (99% pure, CAS No. 80-05-7) was

73 obtained from Sigma-Aldrich Company Ltd., Dorset, UK.

74 The BPA derivative MBP: 4-methyl-2,4-bis(p-hydroxyphenyl)pent-1-ene (99% pure, CAS No.

75 13464-24-9) was synthesised at the University of Exeter (SI (Figure S1).

76

77 **Test organisms**

78 Test organisms were 3rd generation homozygous TG(ERE:GFP)Casper zebrafish (*Danio rerio*)

79 (48), combining a green fluorescent protein (GFP) reporter system for estrogen response element

80 (ERE) activation (45) in a translucent Casper phenotype (50). This translucent model extends the

81 use of fluorescent reporters to life-stages >5 dpf, which would otherwise gain skin pigmentation

82 that interferes with GFP detection (48). This is an important feature of the model, as EDC effects

83 may vary both within a tissue and between body tissues at different life-stages (4,51,52). The life-

84 stages selected for this study represent two key landmarks in CV development: 5 days post

85 fertilisation (dpf) marking formation of the endocardial rings (precursors to the heart valve

86 leaflets); 15 dpf marking elongation of the valve leaflets (53-55). The latter life-stage also

87 corresponds with the depletion of the egg yolk and peaks in metabolism (oxygen consumption)

88 and heart beat rate (56).

89 The zebrafish is an established model for biomedical research on CV development, function and

90 disease (53,55,57), including heart valve (mal)formation (58-61). Despite some basic anatomical

91 differences from the human heart (58,62), the cellular and molecular mechanisms of heart

92 development are highly conserved between zebrafish and humans (55,63) and zebrafish have

93 several major advantages over other vertebrate models. Heart formation (including valvulogenesis

94 and remodelling, outlined in detail in Supporting Information SI Table S1) is completed by 35 dpf

95 (62,63), but a heartbeat is detectable as early as 1 dpf, with blood circulation beginning soon

96 thereafter (64). Standard (resting) heart beat rate in 5-15 dpf embryo-larval zebrafish (160–260

97 beats per minute; bpm) is much closer to resting human foetal heart rate (130–170 bpm) than in

98 rodents (300–600 bpm) (56,65-67). Furthermore, respiration in embryo-larval stages relies mainly

99 on cutaneous diffusion of O_2 and CO_2, rather than transport by convective blood circulation (68),

100 enabling the *in vivo* study of late phenotypes of congenital CV malformations, which would be

101 lethal in mammals (57).

102

103 **Ethical statement**

104 All experimental procedures with zebrafish were conducted in accordance with UK Home Office

105 regulations for the use of animals in scientific procedures and followed local ethical review

106 guidelines and approval processes. Water quality was assessed daily (SI Table S2).

107

108 **Chemical exposure**

109   TG zebrafish embryos/larvae were exposed in the laboratory from 6 hours post fertilisation (hpf)

110   to 5 days post fertilisation (dpf) or from 6 hpf to 15 dpf, to aqueous concentrations of BPA (solvent

111   (0.5% DMSO) control 0; low 100; high 1000 µg/L) or its metabolite MBP (solvent control 0; low

112   2.5; high 25 µg/L) in glass 1L aquaria (n=6 aquaria per exposure treatment), positioned in random

113   order and each containing ~120 randomly assigned embryos. The lower BPA concentration was

114   expected to represent maximum measured human maternal-foetal-placental unit concentrations of

115   up to 105 ng/g (69,70), based on bioconcentration factors ranging from 0.25 to 5.7 in larval and

116   adult zebrafish (39,71,72). Both lower and 10× higher (worst case) BPA concentrations were

117   substantially below maximum tolerable concentrations (48). MBP exposure concentrations were

118   based on a relative potency of 250× compared to BPA, measured *in vivo* in juvenile medaka (43).

119   Stock solutions were prepared by dissolving pure test chemicals in analytical grade dimethyl

120   sulfoxide (DMSO) and then diluting (200×) in 400 mL of embryo culture water (73) to give the

121   desired nominal exposure concentrations in 0.5% DMSO. The pH of stock solutions was checked

122   and adjusted to 7.5, as necessary. For the longer-term (0-15 dpf) exposure, 90% water changes

123   were undertaken every 2 days, after commencing feeding twice a day at 6 dpf with excess <100

124   µm particulate fish food (ZM000) and with *Artemia salinus* nauplii from 10 dpf. Exposure

125   solutions were maintained at 28°C, under a 16h:8h light : dark photoperiod cycle with a 15 min

126   dawn/dusk transition.

127   Concentrations of exposure solutions were measured in three replicate aquaria per exposure

128   treatment at the start and end of each exposure period. Chemical body burden was also measured

129   in whole zebrafish embryo-larvae at 5 dpf, and in composite samples of ×30 hearts extracted from

130   5 dpf embryos (n=3 composite samples per treatment). Heart extraction was performed *en masse*:

131   ×50 larvae per aquarium were disrupted in ice-cold Leibovitz's L-15 Medium (Invitrogen, UK)

132   containing 10% foetal bovine serum, using a 6 ml syringe and 19 gauge needle (74), and ×30 hearts

133   were isolated using a 30 µm mesh sieve followed by manual sorting in ice-cold Leibovitz's L-15

134   Medium under a 5× objective on an Olympus SZX16 microscope (Olympus, UK). Fish/hearts

135   were placed in embryo culture water with a terminal dose of anaesthetic of 2 mg/mL tricaine

136   methanesulfonate (MS222) at pH 7.5, then dried under vacuum, macerated and extracted in a

137   solution of 80:20 water:acetonitrile containing an internal standard. Details of chromatographic

138   separation and mass spectrometry analysis of BPA and MBP in water and fish tissues are provided

139   in the SI (Table S3). The limit of quantitation (LOQ) was 0.05 µg BPA/L and 0.05 µg MBP/L for

140   water, and 0.5 ng BPA/g and 0.5 ng MBP/g for fish tissue. Bioconcentration factors ($BCF_{whole\ body}$

141   and BCF_{heart}) were calculated based on a mean whole body wet weight of 1200 µg for 5 dpf

142   zebrafish larvae and a ventricle weight of 10% of the whole body weight at 5 dpf (75).

143   Following chemical exposure, TG zebrafish larvae were selected randomly from each aquarium

144   and were subject to the following effects analyses, which were conducted at 28°C.

145

146   **Quantifying ERE activation (estrogenicity)**

147   ERE activation was quantified in the atrio-ventricular (AV) and ventricular-bulbus (VB) valves as

148   follows. At 5 and 15 dpf ×6 larvae per replicate aquaria (n=6) were washed and then anaesthetised

149   in 0.1 mg/mL MS222 at pH 7.5 and mounted *in vivo* in 1% low melting agarose in embryo culture

150   water with MS222, and then placed into a glass bottom 35 mm dish (MatTek, Ashland, MA, USA).

151   Larvae were orientated right side down and images were obtained using an inverted compound

152   microscope (Zeiss Axio Observer, Cambridge, UK) with a 10× objective, under consistent GFP

153   excitation for a scanning time of 180 ms, using filter set 38 HE: Excitation BP 470/40 nm, Beam

154   splitter FT 495 nm, Emission BP 525/50 nm. GFP expression was quantified as the relative mean

155   pixel intensity of green fluorescence (relative to the solvent control) in a defined region of interest

156   (ROI) encompassing the heart, using ImageJ software (76).

157

158   **Histopathology of the heart and heart valve leaflets**

159   Histopathology of the heart and heart valve leaflets was conducted on ×6 whole zebrafish larvae

160   per replicate aquaria (n=6) at 5 and 15 dpf, following terminal anaesthesia in 2 mg/mL MS222 at

161   pH 7.5, and destruction of the brain. For visible light microscopy, zebrafish were fixed in Bouin's

162   solution (Sigma Aldrich, Dorset, UK), progressively dehydrated in 70-100% industrial methylated

163   spirits and embedded in paraffin wax. For transmission electron microscopy (TEM), zebrafish

164   were fixed in 2% glutaraldehyde and 2% paraformaldehyde in 0.1M PIPES buffer (pH 7.2) for 24

165   h, washed with buffer (3×5 min) and post-fixed for 1 h in 1% osmium tetroxide (reduced with

166   1.5% w/v potassium ferrocyanide) in 0.1M sodium cacodylate buffer (pH 7.2). After a series of

167   washes in deionised water (3×5 min) the larvae were subject to in-block staining with 1% uranyl

168   acetate for 30 mins, then 3×5 min washes with deionised water and then the larvae were

169   dehydrated through an ethanol gradient and embedded in Spurr resin (TAAB Laboratories,

170   Aldermaston, UK). Sagittal sections were obtained through the midline of the atrium and ventricle

171   (to examine the AV valves). For visible light microscopy, serial sections (5 μm) were obtained

172   and placed on glass slides, stained using Masson's trichrome and examined using a Leitz Diaplan

173   light microscope [×(10-100) magnification] to assess for structural pathologies (focusing on

174   valvular cells and interstitial extracellular matrix). For TEM, 70 nm ultrathin sections were

175   collected on pioloform-coated EM copper slot grids (Agar Scientific, Stansted, UK) and were

176   analysed using a JEOL JEM 1400 operated at 120kV, and images taken [×(3000-20000)

177   magnification] with a digital camera (ES 100W CCD, Gatan, Abingdon, UK) to assess for any

178   ultra-structural effects on the heart valves.

179

180   **Quantifying CV function**

181   Non-invasive video analysis of the heart and dorsal aorta was used to measure multiple

182   cardiovascular (CV) endpoints simultaneously (67). At 15 dpf ×6 larvae per replicate aquaria

183   (n=6), were anaesthetized in 0.1 mg/mL MS222 and embedded right side down in 1% agarose in

184   a single well of a press-to-seal silicon isolator (Sigma-Aldrich, Poole, UK) on a clear microscope

185   slide. The slide was then viewed using an inverted light microscope (Leica DM IRB, Leica

186   Microsystems UK Ltd., Milton Keynes, UK, 5× objective) fitted with two high speed video

187   cameras. The first camera (Grasshopper® GRAS-50S5C-C, Richmond, Canada) recorded

188   ventricular heart beat at 30 frames per second (the atrium was obscured at 15 dpf). The second

189   camera recorded blood flow in the dorsal aorta, caudal to the swim bladder, at 120 frames per

190   second (Grasshopper® GRAS-03K2M-C, Richmond, Canada). Both cameras were focused

191   independently on their respective regions of interest, to ensure optimal image quality, and set to

192   record simultaneously for 5 min; recordings from the last 3 mins were subject to image analysis

193   as follows. Resting (standard) ventricular beat rate (bpm - beats per minute) was measured using

194   MicroZebraLab™ image analysis software (v3.5, ViewPoint, Lyon, France). Resting (standard)

195   aortic blood flow rate (nL/s) was measured using ZebraBlood™ (v1.3.2, ViewPoint, Lyon,

196   France).

197

198   **Quantifying metabolic scope**

199   Metabolic scope, combining scope for growth and scope for movement, were measured in terms

200   of specific growth rate (SGR) (77) and critical swimming speed (U_{crit}) (78), respectively. SGR

201   was calculated by measuring individual standard body length [±0.01 mm from snout to caudal

202   peduncle] of TG zebrafish larvae (×10 per aquarium) under anaesthetic (0.1 mg/mL MS222) at 5

203   and 15 dpf, using an Olympus SZX16 microscope and cellSens^{TM} image analysis software. Since

204   individual fish were not tagged, mean specific growth rate (mean SGR as % standard body length

205   per day) was calculated for each aquarium (Equation 1). Critical swimming speed (U_{critb} as

206   standard body lengths/sec) was then assessed at 15 dpf, by placing ×5 larvae at a time in a

207   cylindrical swim flume of length 25 cm, internal diameter 2 cm and volume 78.55 mL, and

208   increasing laminar water flow incrementally by 1.33 cm/sec every 300 secs (5 mins) until the time

209   to exhaustion for all individual larvae. U_{critb} was calculated based on aquarium-mean standard

210   body length at 15 dpf (Equation 2).

211   **Equations**

212   1) Mean SGR = ((ln SL @15 dpf) – ln SL @ 5 dpf) / T)*100

213   Where SL is mean standard length per aquarium (mm); T is time interval (days)

214

215   2) $U_{critb} = U + (t / t_i * U_i)$

216   Where U is penultimate swimming speed (mean standard body lengths/sec); U_i is velocity

217   increment (1.33 cm/sec); t is time swum in final velocity increment (secs); t_i is time interval for

218   each increment (300 secs).

219

220   **Transcriptomic profiling of heart tissues**

221   Hearts were removed from TG zebrafish larvae following terminal anaesthesia in 2 mg/mL MS222

222   at pH 7.5, followed by destruction of the brain. At 5 dpf ×50 larvae per replicate aquaria (n=4)

223   were disrupted in ice-cold Leibovitz's L-15 Medium (Invitrogen, UK) containing 10% foetal

224   bovine serum, and hearts were extracted *en masse*, as described above. Hearts from larvae of 15

225   dpf were micro-dissected individually using fine tip forceps (Dumont Inox #5SF) and an Olympus

226   SZX16 microscope. Hearts for the 15 dpf larvae were pooled (×30 per aquarium) and then snap

227   frozen in liquid nitrogen. Total mRNA was extracted from each pool of 30 hearts using RNeasy

228   micro-kits with on-column DNase treatment (Qiagen, UK) and RNA integrity (RIN) scores were

229   confirmed to be in the range 7.4-8.7 using an Agilent 2200 TapeStation (Agilent Technologies

230   Ltd. Berkshire, UK).   cDNA libraries were prepared with polyA isolation using Illumina

231   TruSeqTM 2 Stranded mRNA Library Preparation kits and subsequent cluster generation was

232   conducted using TruSeqTM Paired-End Cluster Generation kits (Illumina, San Diego CA, USA).

233   Up to 24 cDNA libraries were prepared for sequencing for each test substance (BPA and MBP):

234   nominally n=4 replicate pooled samples from each of 3 treatment groups (solvent control, low,

235   high exposure), for two time points (5 dpf and 15 dpf). Libraries were sequenced with 12 per lane

236   using an Illumina HiSeq 2500 in standard mode, generating 100 base pair reads (paired-end).

237

238   **Statistical analysis**

239   Prior to statistical analysis, phenotypic data were tested for normality (Anderson–Darling test) and

240   homogeneity of variance (Bartlett's or Levene's tests) using Minitab 16 (Minitab, Coventry, UK).

241   Statistical analysis of phenotypic/functional endpoints was performed using linear mixed effects

242   (lme) models (R-statistics version 3.3.2, R Foundation for Statistical Computing) and all lme

243   models included aquarium as a random effect. A multi-variate MANOVA was used to assess the

244   fixed effect of exposure treatment on cardiovascular function, combining both ventricular heart

245   beat rate and blood flow (using the function 'cbind'). Statistical significance ($p<0.05$) of treatment

246   effects on these and other individual phenotypic endpoints was also determined by 'one-way'

247   comparisons of untransformed heart beat or blood flow data, and lme model fit was measured

248   using the Akaike Information Criterion (AIC). Phenotypic/functional effects data are presented in

249   the text or shown graphically as the mean ± 95% confidence interval.

250   Transcriptomic data were quality-trimmed and filtered (to remove sequencing adapters) and then

251   processed using the TopHat/ Cufflinks pipeline (79), followed by differential gene expression

252   analysis comparing chemical exposure treatments with control treatments using DESeq2 v3.6 and

253   an adjusted p-value of <0.05 set as the false discovery rate (80).

254   Gene Set Enrichment Analysis (GSEA) using DAVID v6.8 (81), Enrichr (82) and Reactome v66

255   (83) was conducted on sets of differentially expressed genes (for each chemical exposure

256   treatment) to identify over-represented Gene Ontology (GO) terms for biological processes and

257   functional pathways, including KEGG v88 (84) and Reactome v66 pathways (83) referenced to

258   the zebrafish (GRCz10) and the human genome (GRCh38.p12).

259   Transcription Factor Binding Site (TFBS) motif enrichment analysis was conducted on 5 and 50

260   kilobase (kB) long DNA flanking sequences both up and downstream of the differentially

261   expressed genes to quantify the potential for estrogen receptor interactions; flanking sequences

262   were retrieved using BioMart from Ensembl v94 (85). Over-represented motifs in each gene set

263   were identified using AME (86) in MEME Suite v5.0.2 (http://meme.nbcr.net). Each gene set was

264   'shuffled' to generate a control gene set (with matched GC content), and enriched TFBS motifs

265   were subsequently identified using the JASPAR 2018 (CORE:vertebrate) database (87).

266   Gene groups were considered to be enriched when enrichment scores (EASE scores) were >1.3,

267   and when *p*-values adjusted for multiple-testing (Benjamini-Hochberg) were < 0.1.

268

269   **RESULTS AND DISCUSSION**

270

271   **Chemical exposure**

272   Mean measured concentrations of aqueous exposure solutions were 104-128% of nominal values

273   for 100 and 1000 µg/L BPA (117 ± 4, 1028 ± 23 µg/L) and 82-113% of nominals for 2.5 and 25

274   µg/L MBP (2.1 ± 0.1, 28.2 ± 0.35), and both sets of controls contained no measurable test chemical

275   (SI Table S4). Mean measured bioconcentration factors for BPA were: 5 day $BCF_{whole\ body}$ = 2.5

276   and 3.8 for 100 and 1000 µg/L BPA exposures, respectively, corresponding with whole body

277   concentrations of ~250 and ~3700 ng/g, which are equivalent to ×2.5 and ×37 maximum human

278   maternal-foetal-placental unit concentrations of 105 ng/g (69,70). Mean measured 5 day BCF_{heart}

279   = 0.09 for the 1000 µg/L BPA exposure was substantially lower than the corresponding BCF_{whole}

280     $_{body}$. The mean measured bioconcentration factor for MBP was: 5 day $BCF_{whole\ body}$ = 27 for the 25

281   µg/L MBP exposure, corresponding with a whole body concentration of 675 ng/g. MBP was not

282   detectable above the LOQ (0.5 ng/g) in heart tissue, so a 5 day BCF_{heart} could not be determined.

283

284   **ERE activation**

285   Exposure to BPA or MBP induced fluorescence from the ERE:GFP reporter in the liver and in the

286   region of interest (ROI) encompassing the heart, specifically in the atrio-ventricular (AV) and the

287   ventricular-bulbus (VB) valves (Figure 1), which is consistent with previous studies (44,48).

288   Higher fluorescence intensity in the heart/valves was not due to chemical partitioning, since heart

289   tissue concentrations for BPA were more than an order of magnitude lower than in whole body

290   tissue (and the water concentration). Instead, greater ERE activation and fluorescence in the heart

291   valves may be due to tissue-specific expression of different ERs and receptor sub-types. Relative

292   mean fluorescence intensity in the ROI (relative to the solvent control) increased with BPA

293   exposure concentration (100 to 1000 µg/L) from 2.2 ± 0.3 to 31 ± 2 at 5 dpf, and showed a similar

294   concentration-related response, increasing from 15.3 ± 1.1 to 26.9 ± 0.2, at 15 dpf. There was a

295   similar response pattern in relative mean fluorescence intensity in the ROI for MBP, increasing

296   with MBP exposure (2.5 to 25 µg/L) from 39 ± 3 to 54 ± 3 at 5 dpf, and from 3.0 ± 0.4 to $14.6 \pm$

297   1.5 at 15 dpf (SI Figure S2). Comparing relative mean fluorescence of MBP versus BPA for the

298   lower-level exposure treatments, which can be assumed to lie on the linear sections of the dose

299   response curves (44,48), we calculated the relative potency of MBP compared to BPA to be 710×

300   at 5 dpf and 23× at 15 dpf (SI Table S5), which is consistent with results from previous *in vivo*

301   studies on zebrafish (39,44), medaka (42,43) and rats (41).

302   Greater potency of MBP compared with BPA may be explained, at least in part, by the

303   bioconcentration of MBP from water (5 day $BCF_{\text{whole body}} = 27$), which was one order of magnitude

304   greater than for BPA. Chemical exposure level- and time- related changes in ERE/GFP expression

305   in zebrafish heart valves are likely to be influenced by range of interacting factors. The lower

306   relative potency of MBP in larvae at 15 dpf, compared with that in 5dpf larvae, followed a net

307   reduction in ERE:GFP fluorescence intensity, possibly corresponding (to some extent) with tissue

308   thickening in older fish. Furthermore, the reduction in fluorescence intensity over time was greater

309   in MBP compared to BPA treatments. These results are consistent with metabolic activation of

310   BPA in fish (42,43,88) and greater metabolic activity in 15 dpf compared to 5 dpf zebrafish larvae

311   (56). The observed variation in levels of ERE activation at these different life stages may also be

312   due in part to age-related variation in the expression of different ERs and receptor sub-types (52).

313

314   **Effects on the structure of the heart valve leaflets**

315   There was qualitative evidence of ultra-structural changes in the AV valve leaflets in both BPA

316   and MBP high-level exposure treatments at 15 dpf. TEM images ($\times$3000-20000 magnification)

317   showed the dislocation of valvular cells and the loss of collagen filaments from the interstitial

318   extra-cellular spaces (Figure 2). In the high-level MBP exposure there were also gross-structural

319   changes in the AV valve leaflets. Light microscopy images ($\times$100 magnification), taken following

320   Masson's trichromatic staining, showed that valve leaflets were misshapen (bent) and that the

321   extra-cellular matrix between the bilayer of valvular cells was narrower and lacked collagen

322   (indicated by the lack of blue stain) compared to solvent controls (Figure 2). Although these ultra-

323   and gross- structural effects were clearly evident, they could not be quantified morphometrically,

324   due to the limited number (n=2 or 3 per treatment) of sagittal sections in which the AV valve

325   leaflets were discernible. No other heart valve pathologies were detected in any other treatment

326   or time point, and there was no evidence of edema to indicate general cardiotoxicity. Histological

327   assessment of ventricular-bulbus (VB) valves was not possible from the sagittal sections taken to

328   assess the AV valves, due to their alternative orientation/alignment.

329

330   **Effects on CV function**

331   There were no discernible effects of BPA exposure on CV function in agreement with a previous

332   study (44), but high-level MBP exposure resulted in a statistically significant reduction (versus

333   solvent controls) in ventricular heart beat rate (218 $\pm$ 4 versus 249 $\pm$ 7 bpm; $p = 0.023$) and aortic

334   blood flow rate (1.55 ± 0.07 versus 1.95 ± 0.06 nL/s; $p = 0.03$) in 15 dpf zebrafish, according to

335   the linear mixed effect model lme(Rate ~ Treatment, random=~1|Tank1) (Figure 3; SI Table S6).

336   These results fall within ranges reported at 28°C for zebrafish aged 3.5 to 21 dpf for resting heart

337   beat rate (160 to 260 bpm) (56,65-67) and resting blood flow rate (500 to 1860 μm/s; equivalent

338   to 0.25 to 2.1 nL/s) (67,89,90). Ontogeny of embryo-larval development in zebrafish is such that

339   heart beat and blood flow rate vary substantially with development time and peak at 10–20 dpf, a

340   period which corresponds with a peak in aerobic metabolism (56). Therefore CV performance is

341   likely to be most critical for our selected life-stage (15 dpf) and reduced CV performance (20%

342   reduction in blood flow rate) could be biologically significant. The proportional reduction in blood

343   flow ($20 \pm 3.6\%$) was greater than for heart beat rate ($12 \pm 2.3\%$), potentially indicating valve

344   prolapse (although note the variation in these CV parameters). We were unable to observe valve

345   function directly because of tissue thickening, nor were we able to demonstrate AV decoupling as

346   being symptomatic of valve prolapse (91), since organ growth prevented imaging of both atrial

347   and ventricular beating at 15 dpf. Nevertheless BPA exposures up to 2500 μg/L have been shown

348   to induce erratic AV beat ratios in 5 dpf zebrafish (44).

349

350   **Effects on metabolic scope**

351   No effects of BPA or MBP were seen on metabolic scope (i.e. SGR and U_{critb}) (SI Figure S3 and

352   Table S7). These energetic measures provide a general indication of individual metabolic scope,

353   i.e. energetic reserves beyond basal metabolism (92). U_{critb} integrates anaerobic as well as aerobic

354   scope for movement (93) and also cardio-respiratory performance (65). The lack of significant

355   effects (despite downward trends for MBP) may have been due to substantial inter-individual

356   variation across the exposure treatments. Inter-individual differences in locomotory performance

357 traits have been observed in larval zebrafish between 3 to 21 dpf, and shown to be due to heritable

358 genetic factors not necessarily related to body size (65). Our test organisms were 3rd generation

359 transgenic zebrafish maintained in up to six spawning groups with 30 fish in each group, therefore

360 genetic variation may have been a confounding factor, but this was not quantified. High inter-

361 individual variation may also be related to larval swimming behaviour, which is characterized by

362 intermittent bursts of swimming (94), such that prolonged swim challenge tests >10 mins may not

363 reliably indicate swimming stamina (65). Our swim challenge tests typically ran for 5-10 mins

364 and mean U_{critb} ranged from 10.7 to 12.6 body lengths/sec, which is comparable to values reported

365 elsewhere, ranging from 13 to 18 body lengths/sec in juvenile and adult zebrafish (95,96).

366

367 **Effects on the heart transcriptome**

368 BPA (100, 1000 µg/L) and MBP (2.5, 25 µg/L) exposures at 5 and 15 dpf resulted in significant

369 (adjusted p-value < 0.1) differential expression (predominantly down-regulated expression,

370 compared to solvent controls) in a range of genes governing heart valve development and function

371 (SI Figures S4-S5; SI Tables S8-S10). The down-regulation of a range of genes by ER signaling

372 (via *esr1, esr2* and heterodimers of these) has been demonstrated elsewhere in humans and

373 mammalian models (97,98). The number of genes affected and the level of effect were greatest at

374 5 dpf for high-level BPA exposure (371 genes: 329 down-regulated by log_2 fold changes of -0.5

375 to -9), followed by low-level BPA exposure (131 genes: 115 down-regulated by log_2 fold changes

376 of -0.9 to -9) and high-level MBP exposure (127 genes: 101 down-regulated by log_2 fold changes

377 of -2.5 to -9). There was some overlap between high and low-level BPA exposures at 5 dpf, with

378 62 genes being common to both treatments, whereas only one gene (elastin microfibril interfacer

379 3 - *emilin3*) was common to both MBP treatments at 5 dpf, due in part to the low number of genes

17

380   (8 genes) that were differentially expressed in the low-level MBP exposure (SI Figure S6 - S7).

381   Collectively however, the genes affected by both BPA and MBP at 5 dpf shared significant

382   enrichment for molecular pathways concerning i) nuclear receptor and calcium signalling

383   (estrogen and (para)thyroid), ii) lipid metabolism and iii) extra-cellular matrix (ECM) interactions

384   (99) (Figure 4; SI Figure S8; SI Tables S8 – S10). ECM-related pathways comprising collagen and

385   cartilage formation and organization were particularly prominent for the high-level MBP exposure,

386   and can be related directly to phenotypic effects on the heart valves observed therein. ECM

387   interactions were found to involve Notch signalling (dre04330) and calcium ion binding

388   (GO:0005509) (SI Table S9) which, along with the afore mentioned pathways (i-iii), have

389   previously been linked to the progression of calcific aortic valve disease (99,100) (CAVD -

390   fibrosis, and subsequent calcification and thickening of the aortic valves), which affects up to 13%

391   of human populations in the western world (99) (see later discussion). At 15 dpf fewer genes were

392   differentially expressed compared to 5 dpf. Although only 5 genes overlapped between time points

393   for the high-level BPA exposure treatment (SI Figure S7), there was gene set enrichment for

394   thyroid hormone synthesis (also seen at 5 dpf for MBP) and for estrogen signalling for the 15 dpf

395   high-level BPA exposure (Figure 4). Both hormone signaling pathways have been highlighted in

396   mammalian studies on BPA (31,101). Overall, gene sets from 15 dpf represented pathways

397   associated with heart function (more so than development), particularly cardiac muscle contraction

398   (SI Tables S8 – S9). Four of the 32 genes down-regulated by the high-level BPA exposure: actinin

399   alpha 3b (*actn3b*), myosin light chain, phosphorylatable, fast skeletal muscle a (*mylpfa*), myosin,

400   heavy polypeptide 2, fast muscle specific (*myhz2*) and troponin I type 2a (skeletal, fast), tandem

401   duplicate 4 (*tnni2a.4*) have previously been identified as potential biomarkers for cardiac disease

402   in animal models, including zebrafish (102). Low level BPA exposure at 15 dpf led to the

403   differential expression of only gene: apolipoprotein Da, duplicate 2 (*apoda.2* transport protein).

404   The transcriptomic effects of high-level MBP exposure at 15 dpf could not be established due to

405   problems encountered in sample processing (PCR amplification during library preparation), while

406   low-level MBP exposure at 15 dpf led to the differential expression of only one (unannotated) gene

407   (*si:dkey-7c18.24*) (SI Figure S7, SI Table S8).

408

409   Analysis of TFBS motif enrichment showed that differentially expressed genes in both BPA and

410   MBP exposures were similarly enriched and were flanked (within 5 kB) by binding sites for

411   transcription factors associated with estrogen receptor signaling, including: estrogen receptor 2

412   (*esr2*); specificity proteins constituting ERE tethering factors (*sp1, sp3, sp4*); pioneer factors

413   facilitating ERE binding (*foxa1, nfkb2, pbx1, runx1*); CAMP responsive element binding proteins

414   (*creb1, creb5*) (SI Figure S9, SI Tables S11 – S13). There was also enrichment for estrogen

415   receptors (*esr1, esr2*) beyond proximal promoter regions, up to 50 kB from differentially expressed

416   genes (SI Table S13). Examination of these findings versus the established roles of estrogen in

417   normal (and abnormal) heart valve development indicate plausible links between substantial ERE

418   activation by BPA and MBP and the observed transcriptomic and phenotypic effects on the heart

419   valves in our zebrafish. Endogenous estrogen (17β-estradiol) is known to be protective of the CV

420   system in later life, which is one of the reasons for hormone replacement therapy in post-

421   menopausal women. The results of studies on the pathogenesis of CAVD share some similarities

422   with the findings in our study (in terms of effect pathways) and also show that major risk factors

423   include polymorphisms of the estrogen receptor (103). Inactivation of estrogen receptors is

424   generally associated with increased calcification of the valve leaflets in diseased patients

425   (104,105). Empirical studies in mammalian models have shown that estrogen inhibits collagen

426 synthesis in rat cardiac fibroblasts (106) and, more specifically, estrogen decreases collagen I and

427 III gene expression in fibroblasts from female rats (107). BPA has also been shown to cause sex-

428 specific alterations in gene expression profiles, changes in the composition of the cardiac collagen

429 extracellular matrix and altered CV function in CD-1 mice (101). Furthermore, disruption of

430 collagen in the extracellular matrix has been shown to directly promote valve leaflet calcification

431 *in vitro* (108). Based on these studies it is entirely plausible that the estrogenic action of high-

432 level MBP exposure led to collagen deficiency and valve weakening in our larval zebrafish. This

433 preliminary (pre-calcification) condition resembles 'myxomatous degeneration' characterized by

434 collagen degradation and elastic fibre fragmentation, resulting in a "floppy" valve that is prone to

435 prolapse and regurgitation (109). As with CAVD, it may be speculated that more progressive

436 effects of MBP (and BPA) on heart valve development and function may occur in the longer- term

437 in zebrafish, but this remains to be proven.

438

439 **Linking cause and effect**

440 Although estrogen is known to be cardio-protective in later life, inappropriate estrogenic

441 exposures, including from estrogenic chemicals, in early life can lead to cardiac malformation

442 (110). We demonstrate that aqueous exposure to the weak estrogen BPA at $1\times$ and $10\times$ maximum

443 human maternal-foetal-placental unit concentrations, or its more potent metabolite MBP, at

444 equivalent potency concentrations, activate estrogen responsive elements (EREs via estrogen

445 receptor signalling) in the heart valves and alter the expression of a range of genes, including

446 several governing CV development and function in embryo-larval zebrafish. BPA and MBP

447 perturbed similar downstream effect pathways, but only the high-level MBP exposure resulted in

448 gross phenotypic effects including, malformation of the AV valves, and reduced heart beat and

449   blood flow, at 15 dpf. Our findings provide a substantial chain of evidence, but further work is

450   required to fully define adverse outcome pathways for the effects of BPA and its metabolites,

451   including MBP, on heart development and function. Longer-term studies, including lower level

452   chemical exposures, are needed, since heart valve formation and remodelling (e.g. AV valve

453   transitioning from two to four leaflets) is not complete in zebrafish until 35 dpf (62,63) and effects

454   may not become functionally manifest until in later life. Vertebrate models with short life spans,

455   such as zebrafish are highly amenable for this work.

456

FIGURES

458

459

Figure 1. GFP fluorescence locating and quantifying ERE activation by BPA and MBP in the

heart in embryo-larval zebrafish

Embryo-larval zebrafish at 5 dpf: a) Solvent control; b) 1000 µg/L BPA; c) 25 µg/L MBP;
d) Close up of the region of interest showing the heart (encircled).

Fluorescence indicating Estrogen Response Element (ERE) activation was concentrated in the
Atrio-Ventricular (AV) and Ventricular-Bulbous (VB) valves.

466

Figure 2. Images of atrio-ventricular (AV) valve leaflets from high-level BPA and MBP exposure treatments versus solvent controls at 15 days post fertilisation (dpf)

Bright field images a-c are shown at ×100 magnification: AV valve leaflets were bent in the high-level MBP exposure. TEM images d-l are shown at ×3000, ×6000 and 20000 magnification: The extra-cellular matrix between the bilayer of valvular cells was narrower and lacked collagen in the high-level BPA and MBP exposure treatments compared to solvent controls (qualitative assessment). Annotations: A = Atrium, V = Ventricle, E = Erythrocytes, Va = Valve leaflet, IS = Interstitial Space, CF = Collagen Fibres, N = Nucleus, Arrow heads indicate bent AV valve leaflet. Scale bar (bottom left in each image): a-c = 10 μm; d-f = 5 μm; g-i = 2 μm; j-l = 1 μm.

Figure 3. Effects of BPA and MBP exposure on cardiovascular function in zebrafish larvae at 15 days post fertilisation (dpf)

Hatched bar charts (A-B) represent BPA, solid bar charts (C-D) represent MBP. Data represent 6 individual fish taken randomly from each of 6 separate aquaria (n=6 experimental replicates) per exposure treatment. Bar heights represent means, error bars represent 95% confidence intervals. Significant differences from 0 µg/L solvent control ($p>0.05$) are highlighted with an asterisk.

Figure 4: Gene set enrichment for KEGG pathways in heart tissues from 5 and 15 day old larval zebrafish in BPA and MBP exposure treatments (versus solvent controls).

Sequence data were generated from hearts pooled from ~30 individuals from each of 4 separate aquaria (nominally n=4 experimental replicates) per exposure treatment. Enriched pathways were identified using Enrichr and referenced to the KEGG database (2016). Pathways highlighted in red boxes are calcific aortic valve disease (CAVD) biomarkers. (Also see enriched Reactome pathways (in SI Figure S10).

500

AUTHOR INFORMATION

Corresponding Author

Corresponding author: Ross Brown, ross.brown@exeter.ac.uk, ++44 7587 702353

Corresponding author address: Biosciences, College of Life and Environmental Sciences
University of Exeter, Lab 201, Geoffrey Pope Building, Stocker Road, Exeter, EX4 4QD, UK

532

533   **SUPPORTING INFORMATION**

534   Tables describing: zebrafish heart and heart valve morphogenesis (valvulogenesis); water quality;

535   test substance analysis; ERE response - relative mean fluorescence intensity induced by BPA and

536   MBP in the heart valves; effects on CV function; specific growth rate (SGR) and critical swimming

537   speed (U_{critb}); differentially expressed genes and enrichment for GO terms, KEGG and Reactome

538   pathways and TFBS motifs in BPA and MBP exposure treatments.

539   Figures showing: Nuclear Magnetic Resonance Spectrum for MBP; relative fluorescence in ERE-

540   GFP transgenic zebrafish larvae following exposure to BPA and MBP; effects of BPA and MBP

541   exposure on specific growth rate (SGR) and critical swimming speed (U_{critb}); heat maps showing

542   differentially expressed genes; Venn diagrams showing overlap in differentially expressed genes

543 for BPA and for MBP exposure treatments and for time points 5 and 15 dpf; cluster plots showing

544 enrichment of Reactome pathways and TFBS motifs in BPA and MBP exposure treatments.

545

546 **ABBREVIATIONS**

547 AIC - Akaike information criterion

548 AV - atrio-ventricular (valves)

549 BCF - bio-concentration factor

550 BPA - bisphenol A

551 CAVD - calcific aortic valve disease

552 CV - cardiovascular

553 DMSO - dimethyl sulfoxide

554 ECM - extra-cellular matrix

555 EDC - endocrine disrupting chemical

556 ER - estrogen receptor

557 ERE - estrogen response element

558 GFP - green fluorescent protein

559 LOQ - limit of quantitation

560 MBP - 4-methyl-2,4-bis(p-hydroxyphenyl)pent-1-ene

561 PCR - polymerase chain reaction

562 ROI - region of interest

563 SGR - specific growth rate

564 TEM - transmission electron microscopy

565 TFBS - transcription factor binding site

566   TG - transgenic

567   VB - ventricular-bulbus (valves)

568

569   **REFERENCES**

570   1) TEDX. TEDX list of potential endocrine disruptors. 2018; URL (accessed 26 June 2018):

571   https://endocrinedisruption.org/interactive-tools/tedx-list-of-potential-endocrine-disruptors/.

572   2) EC European Commission. European workshop on the impact of endocrine disrupters on

573   human health and wildlife. Weybridge, UK. 1996; URL (accessed 1 February 2018):

574   http://www.iehconsulting.co.uk/IEH_Consulting/IEHCPubs/EndocrineDisrupters/WEYBRIDGE

575   .pdf

576   3) WHO IPCS Global assessment of the state-of-the-science of endocrine disruptors

577   WHO/PCS/EDC/02.2.   2002;   URL   (accessed   15   January   2017):

578   http://www.who.int/ipcs/publications/new_issues/endocrine_disruptors/en/

579   4) WHO/UNEP State of the science of endocrine disrupting chemicals − 2012. An assessment

580   of the state of the science of endocrine disruptors prepared by a group of experts for the United

581   Nations Environment Programme (UNEP) and World Health Organisation (WHO). 2012; URL

582   (accessed 15 January 2017): http://www.who.int/ceh/publications/endocrine/en/

583   5) EEA European Environment Agency. The impacts of endocrine disrupters on wildlife, people

584   and their environments. The Weybridge+15 (1996–2011) report. EEA Technical report No 2/2012,

585   ISSN   1725-2237.   2012;   URL   (accessed   March   2018):

586   https://www.eea.europa.eu/publications/the-impacts-of-endocrine-disrupters

587   6) EC European Commission. Endocrine disruptors, strategy, what is being done, priority list.

588   2017;   URL   (accessed   Jan   2018):

589   http://ec.europa.eu/environment/chemicals/endocrine/strategy/being_en.htm

590   7) EPA Environmental Protection Agency. Endocrine Disruption Screening Program for the 21st

591   Century Dashboard. 2017; URL (accessed 10 January 2018): https://actor.epa.gov/edsp21/

592   8) MOE, Ministry of the Environment - Government of Japan. Endocrine Disrupting Effects of

593   Substances. 2017; URL (accessed 2 November 2017): http://www.env.go.jp/en/chemi/ed.html

594   9) Deroo BJ, Korach KS. Estrogen receptors and human disease. *J. Clin. Invest.* 2006, 116(3),

595   561–570. PMID: 16511588, DOI: 10.1172/JCI27987.

596   10) Maggi A, Ciana P, Belcredito S, Vegeto E. Estrogens in the nervous system: mechanisms

597   and nonreproductive functions. *Annu. Rev. Physiol.* 2004, 66, 291-313. PMID: 14977405, DOI:

598   10.1146/annurev.physiol.66.032802.154945.

599   11) Ma L. Endocrine disruptors in female reproductive tract development and carcinogenesis.

600   *Trends.   Endocrinol.   Metab.*   2009,   20(7),   357–363.   PMID: 19709900,   DOI:

601   10.1016/j.tem.2009.03.009.

602   12) EC European Commission. 4th Report on the implementation of the "Community Strategy

603   for Endocrine Disrupters" a range of substances suspected of interfering with the hormone systems

604   of humans and wildlife (COM (1999) 706). Commission staff working paper SEC (2011) 1001

605   final,   Brussels,   DOI: 10.8.2011;   URL   (accessed   1   February   2018):

606   http://ec.europa.eu/environment/chemicals/endocrine/documents/index_en.htm#SubThemes2

607   13) Kortenkamp A, Martin O, Faust M, Evans R, McKinlay R, Orton F, Rosivatz E. State of the

608   art assessment of endocrine disrupters. Final Report to the European Commission Project Contract

609   Number   070307/2009/550687/SER/D3.   2011;   URL   (accessed   March   2018):

610   http://ec.europa.eu/environment/chemicals/endocrine/pdf/sota_edc_final_report.pdf

611   14) Murphy E, Kelly DP. Estrogen signalling and cardiovascular disease. *Circ. Res.* 2011,

612   109(6), 687-696. PMID: 21885836, DOI: 10.1161/CIRCRESAHA.110.236687.

613   15) MRC, Merchant Research & Consulting. Bisphenol A (BPA): 2014 World Market Outlook

614   and Forecast up to 2018. Market Publishers Ltd. 2014; URL (accessed 7 December 2017):

615   http://www.prweb.com/releases/2014/04/prweb11761146.htm.

616   16) Calafat AM, Ye X, Wong LY, Reidy JA, Needham LL. Exposure of the U.S. population to

617   bisphenol A and 4-tertiary-octylphenol: 2003–2004. *Environ. Health Perspect*. 2008, 116(1), 39–

618   44. PMID: 18197297, DOI: 10.1289/ehp.10753.

619   17) US NTP-CERHR - National Toxicology Program Center for the Evaluation of Risks to

620   Human Reproduction. NTP-CERHR Monograph on the potential human reproductive and

621   developmental effects of bisphenol A; 2008. NIH Publication no: 80-5994. URL (accessed 20

622   April 2018): www.cerhr.niehs.nih.gov/chemicals/bisphenol/bisphenol.pdf

623   18) Melzer D, Rice NE, Lewis C, Henley WE, Galloway TS. *Association of urinary bisphenol*

624   *a concentration with heart disease: evidence from NHANES 2003/06. PLoS One* 2010, 5(1), e8673.

625   PMID: 20084273, DOI: 10.1371/journal.pone.0008673.

626   19) FAO/WHO Food and Agriculture Organisation/World Health Organisation. Joint

627   FAO/WHO expert meeting to review toxicological and health aspects of bisphenol A: final report,

628 including report of stakeholder meeting on bisphenol A, 1-5 November 2010, Ottawa, Canada.

629 Publ. WHO, Geneva, Switzerland; 2011 URL (accessed 1 September 2016):

630 http://apps.who.int/iris/bitstream/10665/44624/1/97892141564274_eng.pdf?ua=1

631 20) Careghini A, Mastorgio AF, Saponaro S, Sezenna E. Bisphenol A, nonylphenols,

632 benzophenones, and benzotriazoles in soils, groundwater, surface water, sediments, and food: a

633 review. *Environ. Sci. Pollut. Res*. 2015 22(8), 5711-41. PMID: 25548011, DOI: 10.1007/s11356-

634 014-3974-5.

635 21) EFSA, CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and

636 Processing Aids). Draft Scientific Opinion on the risks to public health related to the presence of

637 bisphenol A (BPA) in foodstuffs. European Food Safety Authority (EFSA), Parma, Italy. 2014;

638 URL   (accessed   1   September   2016):

639 https://www.efsa.europa.eu/sites/default/files/consultation/140117.pdf

640 22) EFSA, CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and

641 Processing Aids). Scientific Opinion on the risks to public health related to the presence of

642 bisphenol A (BPA) in foodstuffs: executive summary. *EFSA Journal* 2015, 13(1), 3978. DOI:

643 10.2903/j.efsa.2015.3978.

644 23) Corrales J, Kristofco LA, Steele WB, Yates BS, Breed CS, Williams ES, Brooks BW. Global

645 assessment of bisphenol A in the environment: review and analysis of its occurrence and

646 bioaccumulation. *Dose Response* 2015, 13(3) PMID: 26674671, DOI:

647 10.1177/1559325815598308.

648   24) Welshons WV, Thayer KA, Judy BM, Taylor JA, Curran EM, vom Saal FS. Large effects

649   from small exposures. I. Mechanisms for endocrine-disrupting chemicals with estrogenic activity.

650   *Environ. Health Perspect*. 2003, 111, 994–1006. PMID: 12826473.

651   25) Okada H, Tokunaga T, Liu X, Takayanagi S, Matsushima A, Shimohigashi Y. Direct

652   evidence revealing structural elements essential for the high binding ability of bisphenol A to

653   human estrogen-related receptor-gamma. *Environ. Health Perspect.* 2008, 116(1), 32-38. PMID:

654   18197296, DOI: 10.1289/ehp.10587.

655   26) Tohmé M, Prud'homme SM, Boulahtouf A, Samarut E, Brunet F, Bernard L, Bourguet W,

656   Gibert Y, Balaguer P, Laudet V. Estrogen-related receptor γ is an in vivo receptor of bisphenol A.

657   FASEB J. 2014;28(7):3124-3133. PMID: 24744145, doi.10.1096/fj.13-240465.

658   27) Wozniak AL, Bulayeva NN, Watson CS. Xenoestrogens at picomolar to nanomolar

659   concentrations trigger membrane estrogen receptor-alpha-mediated Ca2+ fluxes and prolactin

660   release in GH3/B6 pituitary tumor cells. *Environ. Health Perspect.* 2005, 113(4), 431-439. PMID:

661   15811834, DOI: 10.1289/ehp.7505.

662   28) Sheng ZG, Huang W, Liu YX, Zhu BZ. Bisphenol A at a low concentration boosts mouse

663   spermatogonial cell proliferation by inducing the G protein-coupled receptor expression. Toxicol

664   Appl Pharmacol. 2012, 267(1), 88-94. PMID: 23274518. DOI: 10.1016/j.taap.2012.12.014.

665   29) Bromer JG, Zhou Y, Taylor MB, Doherty L, Taylor HS. Bisphenol-A exposure in utero leads

666   to epigenetic alterations in the developmental programming of uterine estrogen response. *FASEB*

667   *J.* 2010, 24(7), 2273-2280. PMID: 20181937, DOI: 10.1096/fj.09-140533.

668   30) Mileva G, Baker SL, Konkle AT, Bielajew C. Bisphenol-A: epigenetic reprogramming and

669   effects on reproduction and behavior. Int J Environ Res Public Health. 2014, 11(7), 7537-7561.

670   PMID: 25054232, DOI: 10.3390/ijerph110707537.

671   31) Moriyama K, Tagami T, Akamizu T, Usui T, Saijo M, Kanamoto N, Hataya Y, Shimatsu A,

672   Kuzuya H, Nakao K. Thyroid hormone action is disrupted by bisphenol A as an antagonist. *J. Clin.*

673   *Endocrinol. Metab.* 2002, 87, 5185–5190. PMID: 12414890, DOI: 10.1210/jc.2002-020209.

674   32) Lee HJ, Chattopadhyay S, Gong EY, Ahn RS, Lee K. Antiandrogenic effects of bisphenol

675   A and nonylphenol on the function of androgen receptor. *Toxicol. Sci.* 2003, 75(1), 40-46. PMID:

676   12805653, DOI: 10.1093/toxsci/kfg150.

677   33) US EPA (Environmental Protection Agency). Bisphenol A (CASRN 80-05-7) Action Plan,

678   3/29/2010,   2010;   URL   (accessed   20   April   2018):

679   https://www.epa.gov/sites/production/files/2015-09/documents/bpa_action_plan.pdf

680   34) EC JRC, European Commission Joint Research Centre. Summary dossier review: Bisphenol

681   A-DRAFT-JRC-2015,   2015;   URL   (accessed   30   November   2017):

682   https://circabc.europa.eu/.../Summary%20dossier%20review_Bisphenol%20A-DRAFT

683   35) Health Canada. Bisphenol A: Update on the Food Directorate's risk management

684   commitments for infant formula. December 15, 2014; URL (accessed 1 December 2017):

685   http://www.hc-sc.gc.ca/fn-an/alt_formats/pdf/securit/packag-emball/bpa/bpa-formula-

686   nourrissons-eng.pdf

687   36) FDA Food and Drug Administration. Update on Bisphenol A (BPA) for Use in Food Contact

688   Applications, Updated November 2014; URL (accessed 1 September 2016):

689   http://www.fda.gov/food/ingredientspackaginglabeling/foodadditivesingredients/ucm064437.htm

690   37) Health Canada. Significant New Activity Notice No. 15290 (Section 85 of the Canadian

691   Environmental Protection Act, 1999) Publication of final decision on the screening assessment of

692   a substance – Phenol, 4,4'-(1-methylethylidene)bis-(bisphenol A),CASNo. 80-05-7 – specified on

693   the Domestic Substances List [subsection 77(6) of the Canadian Environmental Protection Act,

694   1999]; Canada Gazette 2008;142(42); URL (accessed 7 November 2017):

695   www.canadagazette.gc.ca/partI/2008/20081018/html/notice-e.html#d101

696   38) Usman A, Ahmad M. From BPA to its analogues: Is it a safe journey? *Chemosphere* 2016,

697   158, 131-142. PMID: 27262103, DOI: 10.1016/j.chemosphere.2016.05.070.

698   39) Moreman J, Lee O, Trznadel M, David A, Kudoh T, Tyler CR. Acute toxicity, teratogenic,

699   and estrogenic effects of bisphenol A and its alternative replacements bisphenol S, bisphenol F,

700   and bisphenol AF in zebrafish embryo-larvae. *Environ. Sci. Technol.* 2017, 51(21), 12796-12805.

701   PMID: 29016128, DOI: 10.1021/acs.est.7b03283.

702   40) Yoshihara S, Mizutare T, Makishima M, Suzuki N, Fujimoto N, Igarashi K, Ohta S. Potent

703   estrogenic metabolites of bisphenol a and bisphenol b formed by rat liver s9 fraction: their

704   structures and estrogenic potency. *Toxicol. Sci.* 2004, 78, 50–59. PMID: 14691209, DOI:

705   10.1093/toxsci/kfh047.

706   41) Okuda K, Takiguchi M, Yoshihara S. *In vivo* estrogenic potential of 4-methyl-2,4-bis(4-

707   hydroxyphenyl)pent-1-ene, an active metabolite of bisphenol A, in uterus of ovariectomized rat.

708   *Toxicol. Lett.* 2010, 197, 7–11. PMID: 20435109, DOI: 10.1016/j.toxlet.2010.04.017.

709   42) Yamaguchi A, Ishibashi H, Kohra S, Arizono K, Tominaga N. Short-term effects of

710   endocrine-disrupting chemicals on the expression of estrogen-responsive genes in male medaka

711   (*Oryzias latipes*). *Aquat. Toxicol.* 2005, 72, 239–249. PMID: 15820104, DOI:

712   10.1016/j.aquatox.2004.12.011.

713   43) Ishibashi H, Watanabe N, Matsumura N, Hirano M, Nagao Y, Shiratsuchi H, Kohra S,

714   Yoshihara S, Arizono K. Toxicity to early life stages and an estrogenic effect of a bisphenol A

715   metabolite, 4-methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene on the medaka (*Oryzias latipes*). *Life*

716   *Sci.* 2005, 77, 2643–2655. PMID: 15961118, DOI: 10.1016/j.lfs.2005.03.025.

717   44) Moreman J, Takesono A, Trznadel M, Winter MJ, Perry A, Wood ME, Rogers NJ, Kudoh

718   T, Tyler CR. Estrogenic mechanisms and cardiac responses following early life exposure to

719   Bisphenol A (BPA) and its metabolite 4-methyl-2,4-bis(p-hydroxyphenyl)pent-1-ene (MBP) in

720   zebrafish. *Env. Sci. Technol.* 2018, 52(11), 6656–6665. PMID: 29738667, DOI:

721   10.1021/acs.est.8b01095.

722   45) Lee O, Takesono A, Tada M, Tyler CR, Kudoh T. Biosensor zebrafish provide new insights

723   into potential health effects of environmental estrogens. *Environ. Health Perspect.* 2012, 120(7),

724   990-996. PMID: 22510978, DOI: 10.1289/ehp.1104433.

725   46) Brion F, Le Page Y, Piccini B, Cardoso O, Tong S-K, Chung BC, Kah O. Screening

726   estrogenic activities of chemicals or mixtures *in vivo* using transgenic (*cyp19a1b*-GFP) zebrafish

727   embryos. *PLoS ONE* 2012, 7(5), e36069. PMID: 22586461, DOI: 10.1371/journal.pone.0036069.

728   47) Gorelick DA, Iwanowicz LR, Hung AL, Blazer VS, Halpern ME. Transgenic zebrafish

729   reveal tissue-specific differences in estrogen signalling in response to environmental water

samples. *Environ. Health Perspect.* 2014, 122(4), 356–362. PMID: 24425189, DOI: 10.1289/ehp.1307329.

48) Green JM, Metz J, Lee O, Trznadel M, Takesono A, Brown AR, Owen SF, Kudoh T, Tyler CR. High-content and semi-automated quantification of responses to estrogenic chemicals using a novel translucent transgenic zebrafish. *Environ. Sci. Technol.* 2016, 50(12), 6536-6545. PMID: 27227508, DOI: 10.1021/acs.est.6b01243.

49) Green JM, Lange A, Scott A, Trznadel M, Wai HA, Takesono A, Brown AR, Owen SF, Kudoh T, Tyler CR. Early life exposure to ethinylestradiol enhances subsequent responses to environmental estrogens measured in a novel transgenic zebrafish. *Sci. Rep.* 2018, 8(1), 2699. DOI: 10.1038/s41598-018-20922-z.

50) White RM, Sessa A, Burke C, Bowman T, LeBlanc J, Ceol C, Bourque C, Dovey M, Goessling W, Burns CE, Zon LI. Transparent adult zebrafish as a tool for *in vivo* transplantation analysis. *Cell Stem Cell.* 2008, 2(2), 183–189. PMID: 18371439, DOI: 10.1016/j.stem.2007.11.002.

51) vom Saal FS, Akingbemi BT, Belcher SM, Birnbaum LS, Crain DA, Eriksen M, Farabollini F, Guillette LJ Jr, Hauser R, Heindel JJ, Ho SM, Hunt PA, Iguchi T, Jobling S, Kanno J, Keri RA, Knudsen KE, Laufer H, LeBlanc GA, Marcus M, McLachlan JA, Myers JP, Nadal A, Newbold RR, Olea N, Prins GS, Richter CA, Rubin BS, Sonnenschein C, Soto AM, Talsness CE, Vandenbergh JG, Vandenberg LN, Walser-Kuntz DR, Watson CS, Welshons WV, Wetherill Y, Zoeller RT. Chapel Hill bisphenol A expert panel consensus statement: integration of mechanisms, effects in animals and potential to impact human health at current levels of exposure. *Reprod. Toxicol.* 2007, 24(2), 131-138. PMID: 17768031, DOI: 10.1016/j.reprotox.2007.07.005.

752   52) Bondesson M, Hao R, Lin CY, Williams C, GustafssonJ-Å. Estrogen receptor signalling

753   during vertebrate development. *Biochim. Biophys. Acta.* 2015, 1849(2), 142–151. PMID:

754   24954179, DOI: 10.1016/j.bbagrm.2014.06.005.

755   53) Bartman T, Walsh EC, Wen KK, McKane M, Ren J, Alexander J, Rubenstein PA, Stainier

756   DY. Early myocardial function affects endocardial cushion development in zebrafish. *PLoS Biol*.

757   2004, 2(5), E129. PMID: 15138499, DOI: 10.1371/journal.pbio.0020129.

758   54) Martin RT, Bartman T. Analysis of heart valve development in larval zebrafish. *Dev. Dyn.*

759   2009, 238(7), 1796-1802. PMID: 19449301, DOI: 10.1002/dvdy.21976.

760   55) Staudt D, Stainier D. Uncovering the molecular and cellular mechanisms of heart

761   development using the zebrafish. *Annu. Rev. Genet.* 2012, 46, 397-418. PMID: 22974299, DOI:

762   10.1146/annurev-genet-110711-155646.

763   56) Barrionuevo WR, Burggren WW. O2 consumption and heart rate in developing zebrafish

764   (*Danio rerio*): influence of temperature and ambient O2. *Am. J. Physiol.* 1999, 276(2 Pt 2), R505-

765   13. PMID: 9950931.

766   57) Chávez MN, Aedo G, Fierro FA, Allende ML, Egaña JT. Zebrafish as an emerging model

767   organism to study angiogenesis in development and regeneration. *Front. Physiol.* 2016, 8, 7, 56.

768   PMID: 27014075, DOI: 10.3389/fphys.2016.00056.

769   58) Grimes AC, Stadt HA, Shepherd IT, Kirby ML. Solving an enigma: arterial pole

770   development in the zebrafish heart. *Dev. Biol.* 2006, 290(2), 265-276. PMID: 16405941, DOI:

771   10.1016/j.ydbio.2005.11.042.

772 59) Hove JR, Koster RW, Forouhar AS, Acevedo-Bolton G, Fraser SE, Gharib M. Intracardiac

773 fluid forces are an essential epigenetic factor for embryonic cardiogenesis. *Nature* 2003, 421, 172

774 -177. PMID: 12520305, DOI: 10.1038/nature01282.

775 60) Chen IH, Wang HH, Hsieh YS, Huang WC, Yeh HI, Chuang YJ. PRSS23 is essential for

776 the Snail-dependent endothelial-to-mesenchymal transition during valvulogenesis in zebrafish.

777 *Cardiovasc. Res.* 2013, 97(3):443-453. PMID: 23213106, doi.10.1093/cvr/cvs355.

778 61) Vermot J, Forouhar AS, LieblingM,Wu D, Plummer D, Gharib M, Fraser SE. Reversing

779 blood flows act through *klf2a* to ensure normal valvulogenesis in the developing heart. *PLoS Biol.*

780 2009, 7(11), e1000246. PMID: 19924233, DOI: 10.1371/journal.pbio.1000246.

781 62) Sarmah S, Marrs JA. Zebrafish as a vertebrate model system to evaluate effects of

782 environmental toxicants on cardiac development and function. *Int. J. Mol. Sci.* 2016, 17(12), 2123.

783 PMID: 27999267, DOI: 10.3390/ijms17122123.

784 63) Beis D, Bartman T, Jin SW, Scott IC, D'Amico LA, Ober EA, Verkade H, Frantsve J, Field

785 HA, Wehman A, Baier H, Tallafuss A, Bally-Cuif L, Chen JN, Stainier DY, Jungblut B. Genetic

786 and cellular analyses of zebrafish atrioventricular cushion and valve development. *Development*

787 2005, 132, 4193–4204. PMID: 16107477, DOI: 10.1242/dev.01970.

788 64) Stainier DY, Lee RK, Fishman MC. Cardiovascular development in the zebrafish. I.

789 Myocardial fate map and heart tube formation. *Development* 1993, 119, 31–40. PMID: 8275863.

790 65) Gore M, Burggren WW. Cardiac and metabolic physiology of early larval zebrafish (*Danio*

791 *rerio*) reflects parental swimming stamina. *Front. Physiol.* 2012, 3, 35. PMID: 22375123 DOI:

792 10.3389/fphys.2012.00035.

793 66) De Luca E, Zaccaria GM, Hadhoud M, Rizzo G, Ponzini R, Morbiducci U, Santoro MM.

794 ZebraBeat: a flexible platform for the analysis of the cardiac rate in zebrafish embryos. *Sci. Rep.*

795 2014 5, 4, 4898. PMID 25790189, DOI: 10.1038/srep04898.

796 67) Parker T, Libourel P-A, Hetheridge MJ, Cumming RI, Sutcliffe TP, Goonesinghe AC, Ball

797 JS, Owen SF, Chomis Y, Winter MJ. A multi-endpoint *in vivo* larval zebrafish (*Danio rerio*) model

798 for the assessment of integrated cardiovascular function. *J. Pharmacol. Toxicol. Methods.* 2014,

799 69(1), 30-38. PMID: 24140389, DOI: 10.1016/j.vascn.2013.10.002.

800 68) Pelster B, Burggren WW. Disruption of hemoglobin oxygen transport does not impact

801 oxygen-dependent physiological processes in developing embryos of zebrafish (*Danio rerio*).

802 *Circ. Res.* 1996, 79, 358-362. PMID: 8756015, DOI: 10.1161/01.RES.79.2.358.

803 69) Ikezuki Y, Tsutsumi O, Takai Y, Kamei Y, Taketani Y. Determination of bisphenol A

804 concentrations in human biological fluids reveals significant early prenatal exposure. Human

805 Reprod. 2002;17:2839–2841. PMID: 12407035, doi.10.1093/humrep/17.11.2839.

806 70) Schonfelder G, Wittfoht W, Hopp H, Talsness CE, Paul, M, Chahoud I. Parent bisphenol A

807 accumulation in the human maternal-fetal-placental unit. *Environ. Health Perspect*. 2002, 110,

808 A703–A707. PMID: 12417499.

809 71) Lindholst C, Wynne P, Marriott P, Pedersen S, Bjerregaard P. Metabolism of bisphenol A

810 in zebrafish (*Danio rerio*) and rainbow trout (*Oncorhynchus mykiss*) in relation to estrogenic

811 response. *Comp. Biochem. Phy. C.* 2003,135, 169–177. PMID: 12860056, DOI: 10.1016/S1532-

812 0456(03)00088-7.

813   72) Fang Q, Shi Q, Guo Y, Hua J, Wang X, Zhou B. Enhanced bioconcentration of bisphenol A

814   in the presence of nano-TiO2 can lead to adverse reproductive outcomes in zebrafish. *Environ.*

815   *Sci. Technol.* 2016, 50(2), 1005-1013. PMID: 26694738, DOI: 10.1021/acs.est.5b05024.

816   73) ISO. Water Quality Sampling, ISO 5667, Part 16. Guidance on biotesting of samples, 30

817   Wiley-VCH, Weinheim-New York. 1997; URL (accessed 3 April 2018): http://www.iso.org.

818   74) Burns CG, MacRae CA. Purification of hearts from zebrafish embryos. *Biotechniques* 2006,

819   40(3), 278-281. PMID: 16568816.

820   75) Hu N, Sedmera D, Yost HJ, Clark EB. Structure and function of the developing zebrafish

821   heart. *Anat. Rec.* 2000, 60(2), 148-57. PMID: 10993952, DOI : 10.1002/1097-

822   0185(20001001)260:2<148::AID-AR50>3.0.CO;2-X.

823   76) Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis.

824   *Nat. Meth.* 2012, 9(7), 671-675. PMID: 22930834, DOI: 10.1038/nmeth.2089.

825   77) Ricker WE. Growth rates and models. In: Hoar WS, Randall DJ, Brett JR, editors. Fish

826   physiology, volume VIII. Bioenergetics and growth. Academic Press, New York, USA, 1979, p.

827   677-743.

828   78) Brett JR. The respiratory metabolism and swimming performance of young sockeye salmon.

829   *J. Fish Res. Board Can.* 1964, 21, 1183–1226. DOI: 10.1139/f64-103.

830   79) Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn

831   JL, Pachter L. Differential gene and transcript expression analysis of RNA-seq experiments with

832   TopHat and Cufflinks. *Nat. Protoc.* 2012, 7, 562–578. PMID: 22383036, DOI:

833   10.1038/nprot.2012.016.

834   80) Love MI, Huber W and Anders S. Moderated estimation of fold change and dispersion for

835   RNA-seq data with DESeq2. *Genome Biol.* 2014, 15, 550. PMID: 25516281, DOI:

836   10.1186/s13059-014-0550-8.

837   81) Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene

838   569 lists using DAVID bioinformatics resources. *Nat. Protoc.* 2009, 4(1), 44-57. PMID:

839   19131956, DOI : 10.1038/nprot.2008.211.

840   82) Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, Koplev S, Jenkins

841   SL, Jagodnik KM, Lachmann A, McDermott MG, Monteiro CD, Gundersen GW, Ma'ayan A.

842   Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids*

843   *Res.* 2016, 44, Web Server issue gkw377: W90–W97. PMID: 27141961, DOI:

844   10.1093/nar/gkw377.

845   83) Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M, Garapati P, Haw R, Jassal B,

846   Korninger F, May B, Milacic M, Roca CD, Rothfels K, Sevilla C, Shamovsky V, Shorser S,

847   Varusai T, Viteri G, Weiser J, Wu G, Stein L, Hermjakob H, D'Eustachio P. The Reactome

848   Pathway Knowledgebase. *Nucleic Acids Res.* 2018, 4, 46(D1), D649-D655. PMID: 29145629,

849   DOI: 10.1093/nar/gkx1132.

850   84) Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima, K. KEGG: new perspectives on

851   genomes, pathways, diseases and drugs. *Nucleic Acids Res.* 2017, 45, D353-D361. PMID:

852   27899662, DOI: 10.1093/nar/gkw1092.

853   85) Ruffier M, Kähäri A, Komorowska M, Keenan S, Laird M, Longden I, Proctor G, Searle S,

854   Staines D, Taylor K, Vullo A, Yates A, Zerbino D, Flicek P. Ensembl core software resources:

855   storage and programmatic access for DNA sequence and genome annotation. Database 2017,

856   bax020 PMID: 28365736, DOI: 10.1093/database/bax020.

857   86) McLeay RC, Bailey TL. Motif Enrichment Analysis: a unified framework and an evaluation

858   on ChIP data. *BMC Bioinformatics.* 2010, 11, 165. PMID: 20356413, DOI: 10.1186/1471-2105-

859   11-165.

860   87) Khan A, Fornes O, Stigliani A, Gheorghe M, Castro-Mondragon JA, van der Lee R, Bessy

861   A, Chèneby J, Kulkarni SR, Tan G, Baranasic D, Arenillas DJ, Sandelin A, Vandepoele K,

862   Lenhard B, Ballester B, Wasserman WW, Parcy F, Mathelier A. JASPAR 2018: update of the

863   open-access database of transcription factor binding profiles and its web framework. *Nucleic Acids*

864   *Res*. 2018, 46(D1), D260-D266. PMID: 29140473, DOI: 10.1093/nar/gkx1126.

865   88) Yamaguchi A, Ishibashi H, Arizono K, Tominaga N. *In vivo* and *in silico* analyses of

866   estrogenic potential of bisphenol analogs in medaka (*Oryzias latipes*) and common carp (*Cyprinus*

867   *carpio*). *Ecotoxicol. Environ. Saf.* 2015, 120, 198-205. PMID: 26086576, DOI:

868   10.1016/j.ecoenv.2015.06.014.

869   89) Noseworthy PA, Asirvatham SJ. The knot that binds mitral valve prolapse and sudden

870   cardiac death. *Circulation* 2015, 132(7), 551-552. PMID: 26160860, DOI:

871   10.1161/CIRCULATIONAHA.115.017979.

872   90) Fieramonti L, Foglia EA, Malavasi S, D'Andrea C, Valentini G, Cotelli F, Bassi A.

873   Quantitative measurement of blood velocity in zebrafish with optical vector field tomography. *J.*

874   *Biophotonics* 2015, 8(1-2), 52-59. PMID: 24339189, DOI: 10.1002/jbio.201300162.

875   91) Kwon H-B, Wang S, Helker CSM, Rasouli SJ, Maischein H-M, Offermanns S, Herzog W,

876   Stainier DYR. *In vivo* modulation of endothelial polarization by Apelin receptor signalling. *Nat.*

877   *Comms.* 2016, 7, 11805. PMID: 27248505, DOI: 10.1038/ncomms11805.

878   92) Elliott JM. The energetics of feeding, metabolism and growth of brown trout (*Salmo trutta*

879   L.) in relation to body weight, water temperature and ration size. *J. Animal Ecol.* 1976, 45(3), 923-

880   948. DOI: 10.2307/3590.

881   93) Ejbye-Ernst R, Michaelsen TY, Tirsgaard B, Wilson JM, Jensen LF, Steffensen JF, Pertoldi

882   C, Aarestrup K, Svendsen JC. Partitioning the metabolic scope: the importance of anaerobic

883   metabolism and implications for the oxygen- and capacity-limited thermal tolerance (OCLTT)

884   hypothesis. *Conserv. Physiol.* 2016, 4(1). PMID: 27293766 DOI: 10.1093/conphys/cow019.

885   94) Bagatto B, Pelster B, Burggren WW. Growth and metabolism of larval zebrafish: effects of

886   swim training. *J. Exp. Biol.* 2001, 204, 4335-4343. PMID: 11815657.

887   95) Plaut II, Gordon M. Swimming metabolism of wild-type and cloned zebrafish *Brachydanio*

888   *rerio*. *J. Exp Biol.* 1994, 194, 209–223. PMID: 9317659.

889   96) Palstra AP, Tudorache C, Rovira M, Brittijn SA, Burgerhout E, van den Thillart GEEJM,

890   Spaink HP, Planas JV. Establishing zebrafish as a novel exercise model: swimming economy,

891   swimming-enhanced growth and muscle growth marker gene expression. *PLoS ONE* 2010, 5(12),

892   e14483. PMID: 21217817, DOI: 10.1371/journal.pone.0014483.

893   97) Welboren WJ, Stunnenberg HG, Sweep FC, Span PN. Identifying estrogen receptor target

894   genes. *Molecular Oncol.* 2007, 1(2), 138-43. PMID: 19383291, DOI:

895   10.1016/j.molonc.2007.04.001.

896   98) Arnal JF, Lenfant F, Metivier R, Flouriot G, Henrion D, Adlanmerini M, Fontaine C, Gourdy

897   P, Chambon P, Katzenellenbogen B, Katzenellenbogen J. Membrane and nuclear estrogen receptor

898   alpha actions: from tissue specificity to medical implications. Physiol Rev. 2017, 97(3), 1045-

899   1087. PMID: 28539435, DOI: 10.1152/physrev.00024.2016.

900   99) Small A, Kiss D, Giri, J, Anwaruddin S, Siddiqi H, Guerraty M, Chirinos JA, Ferrari, G,

901   Rader DJ (2017). Biomarkers of calcific aortic valve disease. *Arteriosclerosis, Throm. Vasc. Biol*.

902   37(4), 623-632. PMID: 28153876, DOI: 10.1161/ATVBAHA.116.308615.

903   100) Rusanescu G, Weissleder R, Aikawa E (2008). Notch signaling in cardiovascular disease

904   and calcification. *Curr. Cardiol. Rev.* 4(3): 148–156. PMID: 19936191, DOI:

905   10.2174/157340308785160552.

906   101) Belcher SM, Gear RB, Kendig EL. Bisphenol A alters autonomic tone and extracellular

907   matrix structure and induces sex-specific effects on cardiovascular function in male and female

908   CD-1 mice. *Endocrinology*, 2015, 156(3), 882–895. PMID: 25594700, DOI: 10.1210/en.2014-

909   1847.

910   102) Forough R, Scarcello C, Perkins M. Cardiac biomarkers: a focus on cardiac regeneration.

911   *J. Tehran Heart Cent.* 2011, 6(4), 179-86. PMID: 23074366.

912   103) Nordström P, Glader CA, Dahlen G, Birgander LS, Lorentzon R, Waldenstrom A,

913   Lorentzon M. Oestrogen receptor alpha gene polymorphism is related to aortic valve sclerosis in

914   postmenopausal women. *J. Intern. Med.* 2003, 254, 140–146. PMID: 12859695, DOI:

915   10.1046/j.1365-2796.2003.01179.x.

916   104) Bosse Y, Mathieu P, Pibarot P. Genomics: the next step to elucidate the etiology of calcific

917   aortic valve stenosis. *J. Am. Coll. Cardiol.* 2008, 51, 1327–1336. PMID: 18387432, DOI:

918   10.1016/j.jacc.2007.12.031.

919   105) Elmariah S, Mohler ER. The pathogenesis and treatment of the valvulopathy of aortic

920   stenosis: Beyond the SEAS. *Curr. Cardiol. Rep.* 2010, 12(2), 125–132. PMID: 20425167, DOI:

921   10.1007/s11886-010-0089-6.

922   106) Zhou L, Shao Y, Huang Y, Yao T, Lu LM. 17β-Estradiol inhibits angiotensin II-induced

923   collagen synthesis of cultured rat cardiac fibroblasts via modulating angiotensin II receptors. Eur

924   *J. Pharmacol.* 2007, 567, 186–192. PMID:17511985, DOI: 10.1016/j.ejphar.2007.03.047.

925   107) Petrov G, Regitz-Zagrosek V, Lehmkuhl E, Krabatsch T, Dunkel A, Dandel M, Dworatzek

926   E, Mahmoodzadeh S, Schubert C, Becher E, Hampl H, Hetzer R. Regression of myocardial

927   hypertrophy after aortic valve replacement: faster in women? *Circulation* 2010, 14, 122(11 Suppl),

928   S23-8. PMID: 20837918, DOI: 10.1161/CIRCULATIONAHA.109.927764.

929   108) Rodriguez KJ, Piechura LM, Porras AM, Masters KS. Manipulation of valve composition

930   to elucidate the role of collagen in aortic valve calcification. *BMC Cardiovasc. Disord*. 2014, 14,

931   29. PMID: 24581344, DOI: 10.1186/1471-2261-14-29.

932   109) Hinton RB, Yutzey KE. Heart valve structure and function in development and disease.

933   *Ann. Rev. Physiol.* 2011, 3, 29–46. PMID: 20809794, DOI: 10.1146/annurev-physiol-012110-

934   142145.

935   110) Hook EB. Cardiovascular birth defects and prenatal exposure to female sex hormones: A

936   reevaluation of data reanalysis from a large prospective study. *Teratology* 1994, 49, 162-166.

937   PMID: 8059421, DOI : 10.1002/tera.1420490303.